Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277640 | 1.00 | GPR119 (0.41) | GPR119MCHR1PDE4APDE4BPDE4C | |
| SCHEMBL4277638 | 1.00 | GPR119 (0.41) | GPR119MCHR1PDE4APDE4BPDE4C | |
| SCHEMBL3984515 | 0.86 | GPR119 (0.47) | GPR119 | |
| SCHEMBL5082129 | 0.86 | GPR119 (0.46) | GPR119 | |
| SCHEMBL3981368 | 0.86 | GPR119 (0.46) | GPR119 | |
| SCHEMBL3981370 | 0.86 | GPR119 (0.46) | GPR119 | |
| SCHEMBL3980596 | 0.86 | GPR119 (0.46) | GPR119 | |
| SCHEMBL5082136 | 0.86 | GPR119 (0.46) | GPR119 | |
| SCHEMBL3980850 | 0.85 | GPR119 (0.53) | GPR119 | |
| SCHEMBL14190965 | 0.83 | GPR119 (0.60) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885MCHR1 108/4885PDE4A 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.